AstraZeneca
NEWS
Under the collaboration deal with Acerta, Veracyte will offer genomic information in support of Acerta’s oncology development program. Financial details were not disclosed.
MiNA said the collaboration will combine its “expertise in the discovery and development of saRNA therapeutics” with AstraZeneca’s experience in “identifying and bringing breakthrough treatments to patients with metabolic diseases.”
Three months after it won approval in type 2 diabetes, AstraZeneca’s Farxiga is eying potential regulatory win as a treatment in heart failure patients.
Pharma, biotech and life sciences companies boost their leadership ranks with this weeks Movers & Shakers.
AstraZeneca and Merck are closing out 2019 on a high note with another approval for its PARP inhibitor Lynparza.
Specifically, it was approved for adults with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based treatments in the metastatic setting.
Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.
As part of strategic refocusing, AstraZeneca sold the rights to two cancer drugs in several countries in Europe, Africa and other countries to Juvisé Pharmaceuticals.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
JOBS
IN THE PRESS